TABLE 1 .

Protective efficacy in the mouse pulmonary infection and guinea pig keratoconjunctivitis models after intranasal immunization with various doses of S. flexneri 2a Invaplex_NAT or Invaplex_AR

Model and treatment	Dose (μg)	No. of animalsa		% protectionb	P valuec
		Protected	Unprotected
Mouse lung (n = 15)
S. flexneri 2a InvaplexNAT	10	15	0	100	<0.001
	5	15	0	100	<0.001
	2.5	12	3	75	0.003
	1	10	5	59	0.025
	0.1	9	6	50	0.06
S. flexneri 2a InvaplexAR	5	15	0	100	<0.001
	2.5	15	0	100	<0.001
	1	13	2	84	0.001
	0.1	10	5	59	0.025
Saline	None	3	12	N/Ad	N/A
Guinea pig keratoconjunctivitis (n = 12)
S. flexneri 2a InvaplexNAT	25	9	3	75	0.0005
	5	3	9	25	0.22
	1	0	12	0	1.00
S. flexneri 2a InvaplexAR	23	7	5	59	0.0053
	5	7	5	59	0.0053
	1	4	8	33	0.09
Saline	None	0	10	N/A	N/A

^a“Protected” indicates number of survivors in the mouse lung model and number of animals with eyes protected in the keratoconjunctivitis model. “Unprotected” indicates number of dead animals in the mouse lung model and number of animals with unprotected eyes in the keratoconjunctivitis model.

^bPercent protection = (AR for controls − AR for immunized)/AR for controls × 100, where the attack rate (AR) for a group is determined by (number of diseased animals/total number of animals) × 100.

^cFisher exact test.

^dN/A, not applicable.